GPX1 expression promotes stemness and aggressiveness in myxoid liposarcomas

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Sarcomas develop from mesenchymal stromal/stem cells (MSCs), with cancer stem cells (CSCs) driving aggressive behavior.
• Characterizing CSCs is crucial for developing effective sarcoma therapies.

Purpose of the Study:

• To investigate the role of GPX1 in sarcoma progression and CSC enrichment.
• To identify potential therapeutic targets for aggressive sarcomas.

Main Methods:

• Proteomic analysis of adherent and CSC-enriched myxoid liposarcoma cultures.
• GPX1 expression manipulation (depletion and overexpression) in sarcoma cell lines.
• In vivo tumor formation assays.
• Correlation analysis of GPX1 expression with patient prognosis.

Main Results:

• GPX1 expression consistently increased during CSC enrichment in sarcoma models.
• GPX1 depletion reduced proliferation, tumorsphere formation, and in vivo tumor growth.
• GPX1 overexpression enhanced proliferation and tumorsphere formation.
• GPX1 expression correlated with aggressive sarcoma phenotypes and poorer patient outcomes.
• GPX1 silencing affected interferon response, IL6/JAK/STAT3, and NFκB signaling pathways.

Conclusions:

• GPX1 is a key driver of sarcoma CSC aggressiveness and tumor progression.
• GPX1 may serve as a prognostic biomarker for sarcoma patients.
• Targeting GPX1 could be a potential therapeutic strategy for aggressive sarcomas.